DARE - Dare Bioscience, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.9948
-0.0152 (-1.50%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close1.0100
Open1.0000
Bid0.0000 x 800
Ask0.0000 x 28000
Day's Range0.9900 - 1.0100
52 Week Range0.6900 - 2.2200
Volume137,857
Avg. Volume396,645
Market Cap26.508M
Beta (5Y Monthly)1.47
PE Ratio (TTM)N/A
EPS (TTM)-0.8700
Earnings DateAug 12, 2020 - Aug 17, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Daré Bioscience Announces Initiation of Pivotal Phase 3 Study of DARE-BV1 in Patients with Bacterial Vaginosis

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced the initiation of the DARE-BVFREE study, a multi-center, double-blind, placebo-controlled Phase 3 clinical study of DARE-BV1 for the treatment of bacterial vaginosis. DARE-BV1 is an investigational thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% being evaluated as a one-time, vaginally-administered treatment for bacterial vaginosis. The DARE-BVFREE study is expected to enroll approximately 240 participants, ages 12 and older, diagnosed with bacterial vaginosis across multiple clinical sites in the United States.

  • GlobeNewswire

    Daré Bioscience Announces Receipt of $1.5 Million Under the Current Grant Supplement Award for Continued Development of User-Controlled Long Acting Reversible Contraceptive

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced the receipt by its wholly owned subsidiary of $1.5 million in additional grant funding from the Bill & Melinda Gates Foundation. The grant supports ongoing development activities in 2020 for its user-controlled long acting reversible contraceptive program, referred to as DARE-LARC1. DARE-LARC1 has been developed with the support from the foundation in the form of approximately $18 million in grant funding prior to this most recent disbursement.

  • GlobeNewswire

    Daré Bioscience Announces Participation in BIO Digital 2020

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that the company will participate in the BIO International Convention, which will be held in a new, virtual event format for 2020, known as BIO Digital, from June 8-12, 2020. Sabrina Martucci Johnson, President and CEO of Daré Bioscience, will participate in a panel discussion titled Redefining BioPharma in a Female-Forward World and will separately provide a company presentation. Both the panel discussion and company presentation will be available on-demand during the conference for all registered virtual event attendees.

  • Thomson Reuters StreetEvents

    Edited Transcript of DARE earnings conference call or presentation 14-May-20 8:30pm GMT

    Q1 2020 Dare Bioscience Inc Earnings Call

  • GlobeNewswire

    Daré Bioscience Reports First Quarter 2020 Financial Results and Provides Company Update

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today reported financial results for the first quarter ended March 31, 2020 and provided a company update. “The first quarter was an active one for Daré, beginning with the commercial licensing agreement with Bayer for Ovaprene and continuing with important progress in advancing the development of each of our later-stage product candidates,” said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. In addition, we currently believe that we will be able to report topline data for our planned Phase 2b study of Sildenafil Cream, 3.6% in female sexual arousal disorder in 2021 and topline data for our planned pivotal contraceptive study of Ovaprene in 2022.

  • GlobeNewswire

    Daré Bioscience and Health Decisions Form Strategic Partnership to Accelerate the Development of Daré’s Novel Pipeline of Women’s Health Programs

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, and Health Decisions, Inc., a full-service contract research organization (CRO) specializing in women’s health clinical research and diagnostic development, today announced that the companies have signed a partnership agreement under which Health Decisions will exclusively provide CRO services within the United States to support the clinical development of Daré’s innovative pipeline of novel programs designed specifically to address persistent unmet needs in the areas of contraception, fertility, and broader gynecological disorders. Daré and Health Decisions have successfully worked together on prior Daré clinical studies, including the post-coital test clinical study of Ovaprene®.

  • GlobeNewswire

    Daré Bioscience to Host First Quarter 2020 Financial Results and Company Update Conference Call and Webcast on May 14, 2020

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 14, 2020, to review its financial results for the quarter ended March 31, 2020 and to provide a Company update. To access the conference call via phone, dial (844) 831-3031 (U.S.) or (443) 637-1284 (international). The conference ID number for the call is 3387116.

  • GlobeNewswire

    Daré Bioscience CEO to Participate in Maxim Group’s Infectious Disease Virtual Conference

    Daré Bioscience, Inc.(DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will participate in a panel discussion during the Infectious Disease Virtual Conference presented by Maxim Group on May 5, 2020. During the panel discussion, Ms. Johnson will share insights from the Company’s DARE-BV1 development program. DARE-BV1, a novel thermosetting bio-adhesive hydrogel formulated with clindamycin phosphate 2%, is an investigational product for the treatment of bacterial vaginosis (BV), one of the most common vaginal infections.

  • GlobeNewswire

    Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced it entered into a $15 million common stock purchase agreement and registration rights agreement with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor. Under the terms and conditions of the purchase agreement, Daré will have the right, from time to time and at its sole discretion, to sell up to $15 million of its stock to LPC over a 36-month period, subject to a registration statement covering the resale by LPC of shares issued and sold under the purchase agreement being filed and declared effective by the Securities and Exchange Commission (“SEC”) and satisfaction of the other conditions in the purchase agreement.

  • Thomson Reuters StreetEvents

    Edited Transcript of DARE earnings conference call or presentation 30-Mar-20 8:30pm GMT

    Q4 2019 Dare Bioscience Inc Earnings Call

  • GlobeNewswire

    Daré Bioscience Receives Third Notice of Award from National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the Development of Ovaprene®

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced it received a Notice of Award of $730,722 in a grant supporting the Ovaprene® postcoital test (PCT) clinical study research from the Eunice Kennedy Shriver National Institute of Child Health & Human Development, a division of the National Institutes of Health (NIH). The NIH issued this final notice of award for the PCT project after reviewing data from the completed PCT clinical study and commercialization plans for Ovaprene, an investigational hormone-free, monthly contraceptive.

  • ACCESSWIRE

    Dare Bioscience Inc to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 30, 2020 / Dare Bioscience Inc (NASDAQ:DARE) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 30, 2020 at 4:30 ...

  • GlobeNewswire

    Daré Bioscience Reports 2019 Financial Results and Provides a Company Update

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2019 and provided a company update. As a result of the COVID-19 pandemic, these are unprecedented times, circumstances are rapidly evolving, both from a macroeconomic perspective and in our industry, and we will continue to assess our circumstances and development timelines.

  • How Much Are Daré Bioscience, Inc. (NASDAQ:DARE) Insiders Spending On Buying Shares?
    Simply Wall St.

    How Much Are Daré Bioscience, Inc. (NASDAQ:DARE) Insiders Spending On Buying Shares?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...

  • GlobeNewswire

    Daré Bioscience to Host Fourth Quarter and Full-year 2019 Financial Results and Company Update Conference Call and Webcast on March 30, 2020

    SAN DIEGO, March 24, 2020 -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast.

  • GlobeNewswire

    Daré Bioscience Receives FDA Fast Track Designation for DARE-BV1 for the Treatment of Bacterial Vaginosis

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DARE-BV1 for the treatment of bacterial vaginosis (BV) in women. DARE-BV1 was previously granted Qualified Infectious Disease Product (QIDP) designation for the treatment of BV in August 2019.

  • GlobeNewswire

    Daré Bioscience Presents Positive Sildenafil Cream, 3.6% Data Supporting Further Development for the Treatment of Female Sexual Arousal Disorder

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, today announced the presentation of positive findings from a previously reported investigational study that used thermography technology to assess the pharmacodynamics of Sildenafil Cream, 3.6% (Sildenafil Cream) in healthy women. Female Sexual Arousal Disorder (FSAD), a condition characterized primarily by an inability to attain or maintain sufficient genital arousal during sexual activity, is analogous to erectile dysfunction (ED) in men, and sildenafil is the active ingredient in a tablet for oral administration currently marketed under the brand name Viagra® for the treatment of ED in men.

  • GlobeNewswire

    Daré Bioscience to Present at the Cowen 40th Annual Health Care Conference

    SAN DIEGO, Feb. 27, 2020 -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief.

  • GlobeNewswire

    Anika Therapeutics Names Board Member Dr. Cheryl Blanchard as Interim CEO

    Anika Therapeutics, Inc. (ANIK) today announced that Dr. Cheryl Blanchard, a member of the Company’s Board of Directors since August 2018, has been named interim Chief Executive Officer, effective immediately, while the Board continues its search to identify a new CEO following the recent passing of Joseph Darling. In connection with Dr. Blanchard’s appointment, the previously announced interim Office of the President has been dissolved. “We are pleased that Dr. Blanchard, a seasoned executive who has previously served as a biotech President and CEO, has agreed to step in as our interim CEO as we search for Anika’s next leader,” said Dr. Joseph Bower, Chairman of Anika's Board of Directors.

  • GlobeNewswire

    Daré Bioscience Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates

    Daré Bioscience, Inc. (DARE), a leader in women’s health innovation, announced that it has been notified by The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b). As a result, all previously reported Nasdaq compliance matters have been resolved and the previously-scheduled hearing before the Nasdaq Hearings Panel has been canceled. “We believe that 2020 will be a transformational year for Daré,” said Sabrina Martucci Johnson, President and CEO of Daré.

  • GlobeNewswire

    Daré Bioscience to Present at the 2020 BIO CEO & Investor Conference

    SAN DIEGO, Feb. 05, 2020 -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief.

  • GlobeNewswire

    Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

    SAN DIEGO, Jan. 30, 2020 -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, announced that it was notified by the Nasdaq Office of General Counsel.

  • Should You Be Concerned About Daré Bioscience, Inc.'s (NASDAQ:DARE) Historical Volatility?
    Simply Wall St.

    Should You Be Concerned About Daré Bioscience, Inc.'s (NASDAQ:DARE) Historical Volatility?

    Anyone researching Daré Bioscience, Inc. (NASDAQ:DARE) might want to consider the historical volatility of the share...

  • GlobeNewswire

    Daré Bioscience Schedules Conference Call for January 22, 2020 to Discuss Ovaprene® Licensing Agreement and General Corporate Update

    SAN DIEGO, Jan. 15, 2020 -- Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast.